Clinical trials: Respiratory Symptoms
Chronic Lymphocytic Leukemia, CLL
Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia
This non-randomized study will test the safety and effectiveness of Genasense in patients with CLL.
- Trial name
- NCT00021749
- Testing
- Oblimerson sodium, G3139
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Genta Incorporated
Advanced Solid Tumor, Metastatic Cancer
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007, also known as imneskibart, in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung Cancer
- Trial name
- NCT05267626
- Testing
- AU-007, Aldesleukin, Avelumab
- Where
- 17 sites in United States, Australia
- Volunteers
- 159 people
- Sponsor
- Aulos Bioscience, Inc.
Healthy Subjects
HEALSea Nasal Spray for Prevention of Infections in Children
Healsea® Children is a class IIa medical device. This is an isotonic seawater-based nasal spray supplemented with a natural Symbiofilm™ extract (0.02%) isolated from marine bacteria.
- Trial name
- HEALSPIC (NCT06582589)
- Testing
- Healsea Children
- Where
- 8 sites in Bulgaria
- Volunteers
- 139 people, healthy volunteers welcome
- Sponsor
- Lallemand Pharma AG
Chronic Obstructive Pulmonary Disease
Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema
Phase 2a multicenter, randomized, double-blind, placebo-controlled study to assess the pharmacodynamics, efficacy, and safety of tetomilast in patients with emphysema.
- Trial name
- EMPHASIS (NCT00874497)
- Testing
- tetomilast
- Where
- 15 sites in United States
- Volunteers
- 84 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Small Cell Lung Cancer, Soft Tissue Sarcoma
Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.
Tinostamustine (EDO-S101) is a first-in-class alkylating deacetylase inhibitor designed to improve drug access to deoxyribonucleic acid (DNA) strands, induce DNA damage and counteract its repair in cancer cells.
- Conditions
- Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer
- Trial name
- EDO-S101 (NCT03345485)
- Testing
- Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min
- Where
- 13 sites in United States, Canada and 3 more
- Volunteers
- 71 people
- Sponsor
- Mundipharma Research Limited
Moderate Chronic Obstructive Pulmonary Disease, Severe Chronic Obstructive Pulmonary Disease
An Exploratory, Observational, Non-interventional, Open Label, Remote Pilot Study to Assess Adherence in COPD Subjects
The purpose of this study is to monitor adherence to a clothing-attached breathing monitor, respiratory patterns, and activity levels in COPD patients, and correlate those respiratory patterns and activity levels with…
- Trial name
- NCT03745547
- Testing
- Adherence to wearing a Spire wearable health monitor
- Where
- United States
- Volunteers
- 184 people
- Sponsor
- Spire, Inc.
Chronic Obstructive Pulmonary Disease
Home-Based Health Management of COPD Patients
Minnesota HealthSolutions Corporation (MHS) proposes to develop and evaluate a program to motivate and monitor people with chronic obstructive pulmonary disease (COPD) to complete home exercise as part of pulmonary rehabilitation…
- Trial name
- NCT02557178
- Testing
- health coaching
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- Sara Seifert
Rhinitis, Allergic, Seasonal
An Evaluation of the Efficacy and Safety of TOLAMBA™ for Ragweed-Allergic Rhinitis in an Environmental Exposure Chamber
This will be a randomized, double-blind, placebo-controlled, parallel-group, multicenter study. After passing the initial Screening Visit, subjects will be in the environmental exposure chamber(EEC), a room with a controlled…
- Trial name
- NCT00537355
- Testing
- Amb a 1 Immunostimulatory Oligoribonucleotide Conjugate, Histamine
- Where
- 6 sites in Canada
- Volunteers
- 271 people
- Sponsor
- Dynavax Technologies Corporation
Idiopathic Pulmonary Fibrosis
A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of SM04646 Inhalation Solution in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
SM04646-IPF-03 is a Phase 2a, multi-center, open-label study evaluating the safety and efficacy of a single inhaled, nebulized dose of SM04646 solution over a 12-week treatment regimen in subjects with mild to moderate IPF.
- Trial name
- NCT03591926
- Testing
- SM04646
- Where
- 6 sites in Australia, New Zealand
- Sponsor
- Biosplice Therapeutics, Inc.
Chronic Cough
A Study of Gefapixant (MK-7264) in Japanese Adult Participants With Refractory or Unexplained Chronic Cough (MK-7264-038)
The primary objective of this study is to evaluate the safety of two doses of gefapixant (MK-7264) in Japanese adult participants with refractory or unexplained chronic cough.
- Trial name
- NCT03696108
- Testing
- Gefapixant
- Where
- 61 sites in Japan
- Volunteers
- 175 people
- Sponsor
- Merck Sharp & Dohme LLC
Neurogenic Dysphonia, Neurogenic Dysphagia
Neurogenic Dysphonia/Dysphagia Registry
The Neurogenic Dysphonia/Dysphagia Registry is designed to be purely observational (i.e. non-interventional, exploratory). Patient data collected from the registry is expected to be consistent with any information which can be…
- Trial name
- StrongVoice (NCT02493491)
- Where
- 12 sites in United States
- Volunteers
- 146 people
- Sponsor
- Merz North America, Inc.
COPD
24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI
Randomized, Phase IIIb, Two-period, Two-treatment Double-blind, Multi-center, Crossover Study to Evaluate the 24-hour Lung Function Profile in Subjects with Moderate to Very Severe COPD after 4 Weeks of Treatment with PT003 and…
- Trial name
- NCT02347085
- Testing
- GFF MDI (PT003)
- Volunteers
- 43 people
- Sponsor
- Pearl Therapeutics, Inc.
COVID-19
Phase Ⅰ Clinical Trial of a Candidate COVID-19 Vaccine
In this trial, a single-arm, open-label study design will be used to evaluate the safety and tolerability after vaccination with escalating doses of the investigational vaccine (Recombinant COVID-19 Vaccine (chimpanzee adenovirus…
- Trial name
- NCT05706324
- Testing
- Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation
- Where
- Singapore
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Wuhan BravoVax Co., Ltd.
Asthma
ROTAHALER Device Optimization Study
This study will compare the pharmacokinetic (PK) of Fluticasone Propionate/Salmeterol combination (FSC) 100/50 micrograms (mcg) delivered via the capsule-based inhaler (Rdpi) relative to FSC 100/50 mcg delivered via the…
- Trial name
- NCT01890863
- Testing
- Fluticasone Propionate / Salmeterol Xinafoate DISKUS, Fluticasone Propionate / Salmeterol Xinafoate ROTACAP
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Alpha 1-Antitrypsin Deficiency
Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants
The goal of this clinical trial is to assess the safety and tolerability of a single oral dose of BMN 349 in participants with PiZZ or PiMZ/MASH.
- Trial name
- NCT06738017
- Testing
- BMN 349
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 6 people
- Sponsor
- BioMarin Pharmaceutical
Infectious Disease by Haemophilus Influenzae Type b
Immunogenicity and Safety Study of 4th LBVH0101 After the Primary Vaccination in LG-VHCL002 Study
This is a multi-center, comparative, two-arm, parallel-group, single-blind, phase III study to assess immunogenicity and safety of 4th LBVH0101 (Haemophilus influenzae type b tetanus toxoid conjugate vaccine) vaccination compared…
- Trial name
- NCT01251133
- Testing
- LBVH0101 (Hib vaccine), Hiberix™ Vaccine
- Where
- South Korea
- Volunteers
- 122 people
- Sponsor
- LG Life Sciences
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This is a multicenter, randomized, double-blind, double-dummy, parallel group study. The purpose of this study is to compare the efficacy and safety of umeclidinium/vilanterol (UMEC/VI) and fluticasone propionate/salmeterol (FSC)…
- Trial name
- NCT01822899
- Testing
- Umeclidinium bromide/Vilanterol, Fluticasone propionate/Salmeterol
- Where
- 78 sites in Czechia, Denmark and 6 more
- Volunteers
- 717 people
- Sponsor
- GlaxoSmithKline
Asthma, Chronic Obstructive Pulmonary Disease (COPD)
A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)
This study is evaluating the effectiveness of a dose counter for an inhaler device used to deliver medication to people diagnosed with asthma or COPD.
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Chronic Bronchitis
- Trial name
- NCT01302587
- Testing
- Albuterol
- Where
- 25 sites in United States
- Volunteers
- 306 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Fecal Microbiota Transplantation
Metabonomics of COPD and Transplanting of Faecal Bacteria in the Treatment of Its Malnutrition
Oxidative stress can affect the balance of intestinal flora and intestinal structure of patients, resulting in intestinal flora disorder.
- Trial name
- NCT04861649
- Testing
- fecal microbiota transplantation
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Asclepius Meditec Inc.
Chronic Obstructive Pulmonary Disease (COPD), Rheumatoid Arthritis
A Study to Examine the Effect of Particle Size on Bioequivalence and Bioavailability
This study is being conducted to measure the amount of study drug that is in your blood after you receive a different type of tablet in each of four study visits.
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD), Rheumatoid Arthritis, Atherosclerosis
- Trial name
- NCT00517543
- Testing
- GW856553
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.